AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 32 min read$TNGX

Crystal Adam sold $481K of TNGX

Crystal Adam (President, R&D) sold 20,860 shares of Tango Therapeutics, Inc. (TNGX) at $23.06 ($0.48M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Crystal Adam
Published Jun 3, 2026, 10:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TNGX
Neutral
medium confidence
Mentioned
$TNGX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNGXNeutralLow
01

Why it matters

The main trading relevance is sentiment/positioning around insider activity; absent accompanying corporate news, it is unlikely to drive a sustained repricing.

02

Market read

A disclosed, planned insider sale may slightly pressure sentiment, but the 10b5-1 structure limits fundamental interpretation.

03

What to watch

The filing does not reveal whether the officer sold for diversification, liquidity needs, or routine plan execution; holdings remain substantial (115,743 shares after).

Relevance 6/10Novelty 6/10Timing: Filed after-hours (2026-06-03) for a sale executed 2026-06-01

Background

This is an SEC Form 4 insider transaction disclosure (officer/direct holding) for Tango Therapeutics, executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$TNGXNeutralMedium confidence
Context

Tango Therapeutics disclosed an officer (President, R&D) open-market sale of 20,860 shares via SEC Form 4 on a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact unless accompanied by unusual volume or additional disclosures.

Evidence & confidence

Form 4 shows a pre-arranged 10b5-1 sale, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Small read-through for biotech insider-sentiment, but no sector-wide catalyst is indicated.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is on a 10b5-1 plan, the market may overreact; price reaction (if any) could fade quickly.

Key entities

  • issuer
    Tango Therapeutics, Inc.

    Subject of the Form 4 insider sale by its President, R&D.

  • insider
    Crystal Adam

    President, R&D who sold 20,860 shares at ~$23.0558/share under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TNGX insider trading history →

Related articles

SEP 3
$TNGXMedAI 8/10

Tangram Therapeutics PLC: Tangram Therapeutics Announces Progression to Patient Cohorts in Phase 1/2 RESTORE-MASH Trial of TGM-312 and Appointment of Dr Sonya Montgomery as Chief Development Officer

Tangram Therapeutics announced its MASH treatment TGM-312 has progressed to patient cohorts in a Phase 1/2 trial. The company also appointed Dr. Sonya Montgomery as Chief Development Officer. TGM-312 targets liver inflammation and steatosis, with interim data expected in 2027. Dr. Montgomery brings 25 years of experience in clinical development.

finanznachrichten.de2 min
AUG 11
$TNGXMed

Why is Tango Therapeutics stock sliding today?

Tango Therapeutics (TNGX) shares fell about 4% to $26.58 after Q2 2026 results missed expectations. Net loss widened to $0.37 per share versus $0.35 a year earlier, above the ~$0.32 consensus. The quarter again had zero revenue. General and administrative expenses nearly doubled to $22.6M from $11.3M, driven by personnel and share-based comp.

investing.com4 min
AUG 11
$TNGXMed

Tango Therapeutics, Inc. (TNGX): Results of Operations and Financial Condition

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 da

SEC EDGAR 8-K4 min
JUL 15
$TNGXMed

Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues

Canaccord Genuity raised its price target for Tango Therapeutics (NASDAQ:TNGX) to $46 from $42 and kept a Buy rating, citing a revised model that includes combined revenues from vopimetostat plus KRAS inhibitors in NSCLC. Jefferies upgraded TNGX to Buy and lifted its target to $60. Tango also signed an underwriting for about 18.2M shares plus pre-funded warrants, expecting ~$566.5M net proceeds for trials and R&D.

yahoo.com5 min